Press Releases

Upcoming Events

BARDA Industry Day 2019
Tuesday, October 15 - Wednesday, October 16

Washington, D.C.

World Anti-Microbial Resistance Congress 2019
Thursday, November 07 - Friday, November 08

Washington, D.C.

> See all Events
November 22, 2013

VenatoRx has completed a Series A financing round of approximately $3.5M from private investors to complement its other sources of funding and help advance its novel discovery and development programs.

October 22, 2013

VenatoRx received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.

September 16, 2013

VenatoRx was elected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M.

September 16, 2013

In the report, Carbapenem Resistant Enterobacteriaceae was classified as an Urgent treat.

September 01, 2013

VenatoRx was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. VenatoRx may receive up to $3M of funding under the grant.

August 01, 2013

Mr. Milano is the President, Chief Executive Officer, and Chairman of the Board of Directors of ViroPharma.

May 20, 2013

Mr. Felker brings over 20 years of experience in biotechnology, pharmaceutical, and diagnostics, spanning business development, operations, and venture capital.

Archive: 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010